Key statistics
As of last trade, Appili Therapeutics Inc (APLIF:PKC) traded at 0.023, 70.00% above the 52 week low of 0.0135 set on Oct 02, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 0.0251 |
---|---|
High | 0.0251 |
Low | 0.023 |
Bid | -- |
Offer | -- |
Previous close | 0.0254 |
Average volume | 118.65k |
---|---|
Shares outstanding | 121.27m |
Free float | 121.19m |
P/E (TTM) | -- |
Market cap | 4.24m CAD |
EPS (TTM) | -0.0315 CAD |
Data delayed at least 15 minutes, as of Nov 13 2024 18:33 GMT.
More ▼
Press releases
- Aditxt Provides Update on Equity Line of Credit, ATM Usage, and Outstanding Number of Shares
- Aditxt’s Target Acquisition Appili Therapeutics Announces Results of Special Meeting of Shareholders
- Aditxt Acquisition Target Evofem Biosciences Secures Investor Support Through Voting Agreements for Merger with Aditxt's Subsidiary Adifem
- Aditxt’s Target Acquisition Appili Therapeutics Announces Alignment with FDA on Development Requirements for ATI-1801 Topical Antiparasitic Product NDA Submission
- Aditxt To Host Virtual Stakeholder Update and Q&A Session on Friday, November 1, 2024, at 11:30 AM Eastern Time
- Sylvia Hermina Joins Aditxt’s Board of Directors, Elevating Leadership with Broader Perspectives
- Aditxt Completes Final Equity Investment and Key Milestone Under the Amended and Restated Merger Agreement with Evofem
- Aditxt to Host a Virtual Fireside Chat with Aditxt CEO Amro Albanna and Evofem CEO Saundra Pelletier, Moderated by MD & Media Personality Dr. Drew Pinsky, on October 28, 2024, at 11:30 AM Eastern Time
- Aditxt’s Acquisition Target Appili Therapeutics Will Hold a Special Meeting of Shareholders on November 6, 2024, to Vote on the Transaction and Secure Appili’s Shareholder Approval
- Aditxt To Host Stakeholder Update and Q&A Session on Friday, October 11, 2024, at 11:30 AM Eastern Daylight Time
More ▼